This clinical trial aims to evaluate the feasibility and safety of early post-operative brain PET-MRI imaging in adult patients who have undergone surgery for suspected glioblastoma. The study also seeks to validate specific nuclear imaging parameters for better detection of residual tumor tissue compared to standard gadolinium-enhanced MRI. The main objectives are to determine whether early PET-MRI within 48 hours post-surgery is feasible, to assess potential side effects related to imaging procedures, and to explore if PET parameters such as SUVmax, metabolic volume, and tumor-to-striatum ratio can improve the detection of tumor residue. A total of 15 patients will be included at a single site in France. Participants will undergo PET-MRI using 18F-DOPA and gadolinium, and will be monitored for radiation exposure and possible adverse events up to 24 hours after imaging.
First resection for a suspected glioblastoma in the past 72h
Signed informed consent
Deprived of liberty or under legal protection (e.g, guardianship, trusteeship)
Patients under 18 years old
Any postoperative behavioral disorders or medical condition or symptom impeding the completion of brain imaging
Postoperative medical dependency impeding the patient transfer to the nuclear medicine department (including, but not limited to, invasive ventilation, need for external ventricular drainage…)
Postoperative histological diagnosis different from glioblastoma
Beta Emitting Accurate Monitored Systems
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborator